ANCA Vasculitis Market

Market Overview:

The 7 major ANCA vasculitis markets reached a value of US$ 339.0 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 534.3 Million by 2034, exhibiting a growth rate (CAGR) of 4.22% during 2024-2034.

The ANCA vasculitis market has been comprehensively analyzed in IMARC's new report titled "ANCA Vasculitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". ANCA vasculitis refers to a group of autoimmune disorders that cause inflammation of small to medium-sized blood vessels. Some of the symptoms associated with the ailment are fever, fatigue, weight loss, joint pain, and skin rashes. ANCA vasculitis can also cause damage to multiple organs in the body, such as the kidneys, lungs, skin, nerves, etc. Various indications of organ involvement include coughing up blood, shortness of breath, chest pain, blood in the urine, changes in vision or hearing, numbness or tingling in the hands and feet, abdominal pain, etc. In severe cases, the condition can lead to life-threatening complications, such as kidney failure, respiratory ailments, stroke, etc. The diagnosis typically involves a combination of clinical evaluation, laboratory testing, imaging studies, and biopsy. Blood tests to examine the presence of ANCA antibodies are an important diagnostic tool, but a negative result does not necessarily rule out the possibility of ANCA vasculitis. Numerous imaging studies, including CT scans and MRIs, help in detecting damage to the blood vessels and organs affected by the disorder, while a biopsy aids in confirming the diagnosis and determining the extent of organ damage.

The rising cases of immune system dysfunction in which the immune system mistakenly attacks the body's own cells, thereby leading to inflammation and tissue damage, are primarily driving the ANCA vasculitis market. Besides this, the growing prevalence of various associated risk factors, such as genetic mutations, viral infections, certain comorbidities like chronic kidney disease, etc., is also augmenting the market growth. Furthermore, the widespread adoption of glucocorticoids, like prednisone, for reducing inflammation and preventing damage to the blood vessels is creating a positive outlook for the market. Apart from this, the escalating utilization of plasmapheresis to remove harmful antibodies and other substances that contribute to the development of ANCA vasculitis is acting as another significant growth-inducing factor. Moreover, various key players are investing in R&D activities to introduce biomarkers which could help to improve diagnostic accuracy and reduce the need for invasive procedures, like biopsy. This, in turn, is expected to drive the ANCA vasculitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the ANCA vasculitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for ANCA vasculitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ANCA vasculitis market in any manner.

Recent Developments:

• In February 2024, Q32 Bio Inc. published preclinical findings in Molecular Therapy, which demonstrate the therapeutic potential of ADX-097, a tissue-targeted complement inhibitor, for the treatment of ANCA-associated vasculitis.
• In November 2023, Sana Biotechnology, Inc. reported that the US Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to begin a trial of SC291 in patients with several B-cell-mediated autoimmune disorders, including ANCA-associated vasculitis.

Key Highlights:

• The prevalence of ANCA vasculitis is estimated to be between 200 and 400 individuals per million.
• ANCA vasculitis is slightly more prevalent in men than in women (male-to-female ratio ranges from 1.07:1 to 1.48:1).
• The peak age at diagnosis of ANCA-associated vasculitis was 65 to 74 years.
• Approximately 85% to 90% of individuals with GPA, 70% with microscopic polyangiitis, and 30% to 40% with EGPA are ANCA-positive.

Drugs:

Avacopan is an orally given small drug that selectively inhibits the complement C5a receptor C5aR1. By precisely inhibiting the receptor (the C5aR) for the pro-inflammatory complement system component, C5a, on damaging inflammatory cells such as blood neutrophils, avacopan inhibits those cells' ability to cause damage in response to C5a activation, which is believed to be the driver of inflammation. Furthermore, avacopan's specific inhibition of only the C5aR1 allows the favorable C5a l route via the C5L2 receptor to work correctly.

Sparsentan (RE-021, PS-433540) is being developed to treat ANCA-associated vasculitis. It is consumed orally. RE-021 is a dual-acting receptor antagonist (DARA) that targets both the angiotensin II receptor type 1 (AGTR1) and the endothelin A receptor.

Belimumab is the first medication in a class known as BLyS-specific inhibitors. It is available in two forms: lyophilized powder for solution and solution for intravenous and subcutaneous injection.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the ANCA vasculitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the ANCA vasculitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current ANCA vasculitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the ANCA vasculitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2034?
• What was the country-wise size of the ANCA vasculitis market across the seven major markets in 2024 and what will it look like in 2034?
• What is the growth rate of the ANCA vasculitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of ANCA vasculitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of ANCA vasculitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of ANCA vasculitis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with ANCA vasculitis across the seven major markets?
• What is the size of the ANCA vasculitis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of ANCA vasculitis?
• What will be the growth rate of patients across the seven major markets?
   

ANCA Vasculitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for ANCA vasculitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ANCA vasculitis market?
• What are the key regulatory events related to the ANCA vasculitis market?
• What is the structure of clinical trial landscape by status related to the ANCA vasculitis market?
• What is the structure of clinical trial landscape by phase related to the ANCA vasculitis market?
• What is the structure of clinical trial landscape by route of administration related to the ANCA vasculitis market?